Board MeetingApr 29, 2026, 08:31 AM
RNXT to Host Q1 2026 Earnings Call on May 14
AI Summary
RenovoRx, Inc. (RNXT) announced it will host its first quarter 2026 financial results and business highlights conference call on May 14, 2026, at 4:30 pm ET. Management is expected to discuss positive commercial momentum for RenovoCath sales, including increased presence in high-volume institutions and rising repeat orders. The company will also provide an update on its clinical program developments, including the Phase III TIGeR-PaC trial, which is nearing full enrollment and remains on track for completion in the first half of 2026, with final data anticipated in 2027.
Key Highlights
- RNXT to host Q1 2026 financial results and business highlights conference call on May 14, 2026, at 4:30 pm ET.
- Management to highlight positive commercial momentum for RenovoCath sales.
- Phase III TIGeR-PaC trial nearing full enrollment, on track for H1 2026 completion.
- Final TIGeR-PaC data anticipated in 2027.
- Company to outline strategy for post-marketing registry studies and investigator-initiated trials.
- RenovoCath generated approximately $1.1 million in sales in its first full year of commercial efforts.
Price Impact
More from RNXT